

Methylglyoxal, the glyoxalase pathway and advanced glycation endproducts in type 2 diabetes and cardiovascular disease

Citation for published version (APA):

Hanssen, N. (2015). *Methylglyoxal, the glyoxalase pathway and advanced glycation endproducts in type 2 diabetes and cardiovascular disease*. Maastricht University. <https://doi.org/10.26481/dis.20150520nh>

Document status and date:

Published: 01/01/2015

DOI:

[10.26481/dis.20150520nh](https://doi.org/10.26481/dis.20150520nh)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Valorization

Future directions and applications of the glycation pathways to improve clinical management of T2DM and CVD

Using the glycation pathways to better predict CVD in individuals with and without diabetes

In an ideal situation we would be able to identify individuals at high risk of CVD, and treat them appropriately with risk-modifying medication and life-style changes to reduce their risk before an actual CVD-event takes place. Several risk-markers identify individuals at higher risk of CVD, such as older age, male sex, high blood-pressure, smoking and an unfavorable lipid profile (high LDL-cholesterol, low HDL-cholesterol).⁴⁴ In addition, diabetes itself is a strong risk-factor for CVD. Despite the identification of these risk markers and development of integrated risk-scores to calculate an estimated individual risk of CVD with these variables, it is still very difficult to precisely estimate which individuals will develop CVD and which individuals will remain event free, especially in individuals with diabetes.⁴⁵ As a result, many patients receive insufficient treatment, while others receive treatment from which they do not benefit. Therefore, it is important to study the underlying mechanisms of atherosclerosis, as this may help to identify new risk markers. When these risk markers reflect the underlying disease of a patient these risk markers are called biomarkers. Biomarkers, as measured in blood or urine of a patient, may improve the discrimination between patients with either a high or a low risk of cardiovascular events, which can subsequently be used to improve their treatment. This thesis provides a proof of principle that AGEs measured in the circulation may serve as biomarkers of increased risk of incident CVD. However, the plasma measurements we reported in this thesis displayed some limitations for use in clinical practice, such as associated confounding factors, including obesity. The possibility to measure plasma levels of AGE precursors, protein-bound and free AGEs in circulating cells and free AGEs in urine are all promising and essential steps to translate the findings summarized in this thesis into validated biomarkers which can actually improve risk prediction of CVD. This will be a major focus of future research. Future studies should also investigate the extent to which AGE measurements may serve as biomarkers for risk of microvascular complications of diabetes (retinopathy, neuropathy and nephropathy) in individuals with T2DM. Furthermore, as we identified inflammation and hypoxia as additional sources of AGE accumulation, AGE measurements may also be useful biomarkers in other diseases as well, such as rheumatoid arthritis and chronic obstructive pulmonary disease. In addition to identifying individuals at increased risk of CVD, AGE measurements may identify individuals that would particularly benefit from AGE-

lowering treatments. Such an approach may not only improve the identification of high-risk patients, but also the selection of optimal treatment strategies.

The glycation pathways as potential targets to treat CVD

As we show in this thesis that higher levels of specific AGEs are associated with a higher risk of CVD, it may be worth considering whether reducing AGE levels decrease CVD-risk. Several compounds have been identified that lower AGE levels and/or inhibit AGE formation. The best characterized inhibitor of AGE formation is aminoguanidine.⁴⁶ Administration of this compound has been shown to reduce plaque formation in diabetic ApoE^{-/-} mice.⁴⁰ In addition to AGE- and MGO-lowering properties, aminoguanidine has been described as an antioxidant⁴⁷ and inhibitor of nitric oxide formation.⁴⁸ Likewise, pyridoxamine (a vitamin B6 vitamer) is considered an AGE-inhibitor, with anti-oxidant and anti-inflammatory properties,⁴⁹ and has been shown to reduce atherosclerosis in diabetic ApoE^{-/-} mice.⁴¹ Alagebrium is a compound that has been reported to break pre-existing AGE-crosslinks and has also been shown to lower MGO levels directly.⁵⁰ Indeed, alagebrium has been shown to reduce atherosclerosis in diabetic ApoE^{-/-} mice, although it is unclear if its beneficial effect is attributable to its AGE- or MGO-lowering properties.⁴⁰

Whether these compounds also hold promise as treatment for CVD in humans has still not been determined.⁵¹ Unfortunately, aminoguanidine, when administered to people seemed to induce glomerulonephritis,⁵² and has therefore been deemed unsafe as a drug for humans. Therefore, there still is a need to develop and test new AGE inhibitors. Interestingly, established drugs to treat CVD, such as simvastatin, have also been shown to reduce the accumulation of AGEs in human carotid plaques.⁶ Similarly, several glucose-lowering¹⁶ and antihypertensive compounds³⁴ have also been shown to have AGE-lowering properties. Elucidating whether beneficial effects of these drugs are partly attributable to AGE-lowering is clearly relevant, as most of these drugs been shown to have beneficial effects beyond their glucose-,⁵³ lipid-,⁵⁴ and blood pressure-lowering.⁵⁵ Indeed, these characteristics could perhaps be further exploited by increasing their capacity to decrease AGE levels.

The reduction of dietary intake of AGEs may be an alternative strategy to reduce the risk of CVD. Especially processed foods as well as foods prepared by dry heat are thought to contain high levels of AGEs. Whether a diet low in AGEs or AGE-precursors leads to a reduction in AGE levels in the body is a topic that is currently hotly debated. Experimental studies have shown that the uptake of dietary AGEs is around 10-30%,⁵⁶ and that kidneys rapidly excrete excess free AGE fractions. Therefore, a diet low in AGEs may be particularly useful for patients with kidney failure. In animal studies, a diet low in AGEs reduces insulin resistance and atherosclerosis as well as diabetic neuropathy and nephropathy.⁵⁷ However, randomized clinical trials investigating beneficial effects of dietary regimens low in AGEs are rare, and contain only small

numbers of participants.⁵⁸ Therefore, larger clinical studies on this topic are urgently needed.

Based on findings reported in this thesis, boosting the activity of the glyoxalase pathway does not appear to be an attractive approach to treat CVD. As outlined earlier, we could not show any beneficial effect of GLO1 overexpression on plaque burden or phenotype in ApoE deficient mice. However, before we dismiss the glyoxalase pathway as a promising target in CVD, additional animal studies are needed to investigate the role of GLO1 in plaque regression and specifically to assess mice that are challenged to high MGO levels. An additional interesting direction for future research would be to develop compounds that remove inactivating posttranslational modifications from the GLO1 enzyme. Nevertheless, GLO1 remains an attractive target for diabetic microvascular complications.

In conclusion, the glycation pathways may be promising targets improve both prediction and treatment of CVD, and are therefore deserving of further investigation.

References

1. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. *Circ Res* 2014;114:1852-1866.
2. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. *Circulation* 2002;105: 2708-2711.
3. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. *Cardiovasc Res* 2004;63:582-592.
4. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. *Am J Pathol* 1995;147:654-667.
5. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. *Am J Pathol* 1993;143:1649-1656.
6. Cuccurullo C, Iezzi A, Fazio ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Uchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. *Arterioscler Thromb Vasc Biol* 2006;26: 2716-2723.
7. Baidoshvili A, Niessen HW, Stoker W, Huybregts RA, Hack CE, Rauwerda JA, Meijer CJ, Eijssman L, van Hinsbergh VW, Schalkwijk CG. N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. *Atherosclerosis* 2004;174:287-292.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001;414: 813-820.
9. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. *Chem Biol Interact* 1998;111-112:137-151.
10. Ewaschuk JB, Naylor JM, Zello GA. D-lactate in human and ruminant metabolism. *J Nutr* 2005;135: 1619-1625.
11. Talasniemi JP, Pennanen S, Savolainen H, Niskanen L, Liesivuori J. Analytical investigation: assay of D-lactate in diabetic plasma and urine. *Clin Biochem* 2008;41:1099-1103.
12. Ratliff DM, Vander Jagt DJ, Eaton RP, Vander Jagt DL. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II—a clinical research center study. *J Clin Endocrinol Metab* 1996;81:488-492.
13. Thornalley PJ, Hooper NI, Jennings PE, Florkowski CM, Jones AF, Lunec J, Barnett AH. The human red blood cell glyoxalase system in diabetes mellitus. *Diabetes Res Clin Pract* 1989;7:115-120.
14. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnolzer M, Lasitschka F, Neuhofer WL, Kichko TI, Konrade I, Elvert R, Mier W, Pirags V, Lukic IK, Morcos M, Dehmer T, Rabbani N, Thornalley PJ, Edelstein D, Nau C, Forbes J, Humpert PM, Schwaninger M, Ziegler D, Stern DM, Cooper ME, Haberkorn U, Brownlee M, Reeh PW, Nawroth PP. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. *Nat Med* 2012; 18:926-933.
15. Miller AG, Tan G, Binger KJ, Pickering RJ, Thomas MC, Nagaraj RH, Cooper ME, Wilkinson-Berka JL. Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. *Diabetes* 2010;59:3208-3215.
16. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. *Diabetes* 1999;48:198-202.
17. Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. *Gene* 1999;240:149-155.